Pharmaceuticals Company

Wells Pharma

14%

Funding Goal $5,000,000
Funding Raised So Far $600,000
Funding Commitments $100,000
Funding Remaining $4,300,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview


Wells Pharma is disrupting the $5.5B prefilled surgical IV bag and syringe market that has traditionally been produced in hospitals; by providing higher quality, better shelf life and reducing costs.

Wells Pharma provides hospitals and their patients with life-saving drugs when they need them most. We aim to help patients and healthcare facilities get their life-saving drugs as quickly and safely as possible, saving hospitals and surgery centers time and money.

REASONS TO INVEST

• BE PART OF THE SOLUTION: Wells Pharma delivers life-saving medications to Hospitals and Surgery Centers across the nation. Our products are cost-effective, saving Hospitals and Surgery Centers millions of dollars a year.

• JOIN THE TEAM: Wells Pharma has already made the investments to overcome the barriers to entry required to achieve success in this market. The Company is FDA Registered, licensed in 48 states, and has built out the infrastructure necessary for a competitive advantage. The Company's 2022 revenues were in excess of $7M and the Company will achieve $1.25M in gross revenue in January 2023 at a $15M run-rate and growing.

• EXPERIENCE MATTERS: Investing founders and our management team are experienced and have a proven track record of creating value for investors and have already raised over $18M.

LSE, Inc. (DBA Wells Pharmaceuticals, "Wells Pharma") is offering 1,000,000 Class A1 common shares, non-voting at $5.00 per share with a pre-money valuation of $34M.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Business Summary


Company Age 4 years, 2 months
Employees 60
Sub-Industry Drug Manufacturer
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Products/Services


Ready-To-Use prefilled IV bags and syringes for hospitals and surgery centers nationwide.

As a 503B outsourcing facility, Wells Pharma is able to provide large batches of lifesaving Compounded Sterile Preparations (CSPs) that we supply to Acute Care Hospitals and Ambulatory Surgery Centers Nationwide. By delivering our CSPs to these healthcare facilities, we are disrupting the industry by reducing pharmaceutical waste, increasing patient safety, and providing cost savings.

Management


Gary Shapiro
Chairman
Gary S......

Chairman and Founding Principal, has more than 30 years of experience in private equity investment and merchant banking. Mr. S...... has founded or acquired, managed and sold several privately held businesses and has been principal investor in more than 30 companies which have produced substantial realized gains for investors. He is a graduate of Rider University with a BS in Commerce and is the past Chairman of the Board of Trustees and current Trustee of Rider University.

Tony Schwartz
President
Tony S......

Mr. S...... has an extensive career and experience in the pharmaceutical industry spanning 25 years with such companies as J&J, Abbott Labs, Elan Pharma, and The Medicines Company. Since 2002, Mr. S...... has served the hospital segment of the business and has made significant contributions to drive revenues and improve the "bottom line" in all of his roles. Mr. S...... also spent two years of his career with ROi, a Group Purchasing Organization (GPO) serving as the General Manager and Executive Director of the 503B Facilities and Contracts. He has built and nurtured many relationships with hospital systems and within the pharmaceutical industry. His knowledge and expertise has been evident here at Wells and he continues to drive the business initiatives of the company and bring value to shareholders.

Andy Corbin
Chief Financial Officer
Andy C......

Andy is an accomplished executive leader in operations, finance, and technology-driven systems with more than 20 years of experience in the healthcare, digital healthcare, and pharmaceutical compounding facilities. He joins Wells Pharma of Houston, LLC. as CFO. Andy has held several C-Level positions with Sage Software Healthcare Division, StayWell Health Management, LifeLock, and most notably as WebMD's Corporate CFO and CEO of WebMD Practice Services Software Division. Most recently Andy was President and CFO at a 503B Outsourcing Facility where he opened and operated a built-for-purpose 42,000 square-foot manufacturing plant. Andy’s wealth of experience makes him a great addition to the Wells Pharma Team.

Theaquiata Mitchell
Vice President Quality Assurance
Theaquiata M......

Theaquiata M...... has nearly 20 years of experience in quality. As a Quality Assurance professional, she joined Wells Pharma of Houston, LLC with a vast array of skills in Regulatory Compliance for Pharmaceutical, Medical Device, and Ambient and Frozen Tissue for Implants, as well as Validation and Environmental Safety and Health experience. Additionally, Mrs. M...... has experience in the 503B market, having worked for one of the leading companies at the time (PharMEDium). Mrs. M...... brings her knowledge and skills to Wells and has had an excellent track record in meeting and exceeding the regulatory environment of the 503B market.

Investors/Lenders


Family Wealth Office
Affiliates of National Financial Companies (nfcllc.com)

National Financial Copanies is a Merchant Banking Firm established in 1991 to pursue high growth opportunities . Partners and associated parties have invested in and successfully exited over 30 companies in healthcare, pharmacy, financial services, manufacturing and consumer products

Amount
Investment Type
Investment Round
Investment Date

14%

Funding Goal $5,000,000
Funding Raised So Far $600,000
Funding Commitments $100,000
Funding Remaining $4,300,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents


Contact


Wells Pharma

Houston, TX 77054, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).